LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

Search

Crinetics Pharmaceuticals Inc

Închisă

SectorSănătate

42.67 -3.04

Rezumat

Modificarea prețului

24h

Curent

Minim

41.93

Maxim

42.69

Indicatori cheie

By Trading Economics

Venit

-14M

-130M

Vânzări

-888K

143K

Marjă de profit

-90,972.727

Angajați

437

EBITDA

-12M

-142M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+87.78% upside

Dividende

By Dow Jones

Următoarele câștiguri

26 feb. 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

681M

4.7B

Deschiderea anterioară

45.71

Închiderea anterioară

42.67

Sentimentul știrilor

By Acuity

19%

81%

38 / 352 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Weak Bullish Evidence

Crinetics Pharmaceuticals Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

13 feb. 2026, 16:32 UTC

Câștiguri

Enbridge, TC Energy Investing in Opportunities to Tap Rising Energy Demand, Boom in Data Centers -- Update

13 feb. 2026, 21:57 UTC

Câștiguri

Stocks Rise on Softer Inflation Data, but AI Jitters Trigger Worst Week Since November -- WSJ

13 feb. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

13 feb. 2026, 21:20 UTC

Câștiguri

Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More Stock Market Movers -- Barrons.com

13 feb. 2026, 21:05 UTC

Achiziții, Fuziuni, Preluări

Constellation Software: Lumine Group Completes Acquisition of Synchronoss Technologies >CSU.T SNCR

13 feb. 2026, 20:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

13 feb. 2026, 20:45 UTC

Market Talk

Dollar Pares Down Early Losses -- Market Talk

13 feb. 2026, 20:39 UTC

Market Talk

Potential for Mild Winter Ahead Sinks Natural Gas for Week -- Market Talk

13 feb. 2026, 20:28 UTC

Market Talk

Oil Settles Week Lower -- Market Talk

13 feb. 2026, 19:51 UTC

Câștiguri

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More -- Barrons.com

13 feb. 2026, 19:32 UTC

Market Talk

Gold and Silver Climb to Finish Week In Positive Territory -- Market Talk

13 feb. 2026, 19:32 UTC

Market Talk

Gold and Silver Climb to Finish Week In Positive Territory -- Market Talk

13 feb. 2026, 19:29 UTC

Câștiguri

Big Tech's Spending Spree Could Limit Buybacks and Dividends -- Barrons.com

13 feb. 2026, 18:18 UTC

Achiziții, Fuziuni, Preluări

Exxon, Walmart and 9 Other Stocks That Are Soaring Because Cash Is King Again -- Barrons.com

13 feb. 2026, 17:52 UTC

Câștiguri

Pinterest's Earnings Give More Proof of Meta Platform's Dominance -- Barrons.com

13 feb. 2026, 17:16 UTC

Câștiguri

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More -- Barrons.com

13 feb. 2026, 17:10 UTC

Achiziții, Fuziuni, Preluări

Vibe-Coding in Gas Town? A Guide to the Software Selloff With 4 Sexy Stock Picks. -- Barrons.com

13 feb. 2026, 16:59 UTC

Câștiguri

AppLovin Stock Stabilizes After Selloff. Its Biggest Critic Waves the White Flag. -- Barrons.com

13 feb. 2026, 16:39 UTC

Achiziții, Fuziuni, Preluări

Berkshire Might Have Sold More Apple, Bank of America Stock in Fourth Quarter -- Barrons.com

13 feb. 2026, 16:11 UTC

Câștiguri

Nvidia Stock Wobbles. The Focus Is Turning to Earnings. -- Barrons.com

13 feb. 2026, 16:07 UTC

Market Talk

Hungarian Forint Could Rise Further -- Market Talk

13 feb. 2026, 15:54 UTC

Câștiguri

Detroit Automakers Take $50 Billion Hit as EV Bubble Bursts -- WSJ

13 feb. 2026, 15:26 UTC

Market Talk

Indian Imports of Saudi Crude Hit Highest Since 2022 -- Market Talk

13 feb. 2026, 15:01 UTC

Câștiguri

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Steel Dynamics, Coinbase, DraftKings, Tri Pointe Homes, and More -- Barrons.com

13 feb. 2026, 15:00 UTC

Câștiguri

Expedia Falls, but Airbnb Rises. Why Online Travel Stocks Face a Tough Year. -- Barrons.com

13 feb. 2026, 14:50 UTC

Market Talk

Oil Moves Lower As Market Weighs Geopolitical Risk -- Market Talk

13 feb. 2026, 14:44 UTC

Câștiguri

Arista Networks Stock Climbs. Why It Is Outshining Cisco. -- Barrons.com

13 feb. 2026, 14:22 UTC

Market Talk
Câștiguri

Global Energy Roundup: Market Talk

13 feb. 2026, 14:21 UTC

Market Talk
Câștiguri

TC Energy's Broadly Anticipated Results Expected To Have Neutral Response -- Market Talk

13 feb. 2026, 14:13 UTC

Market Talk

U.S. Natural Gas Futures Move Lower -- Market Talk

Comparație

Modificare preț

Crinetics Pharmaceuticals Inc Așteptări

Obiectiv de preț

By TipRanks

87.78% sus

Prognoză pe 12 luni

Medie 89.4 USD  87.78%

Maxim 105 USD

Minim 67 USD

În baza a 11 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruCrinetics Pharmaceuticals Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

11 ratings

11

Cumpărare

0

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

30.39 / 33.46Suport & Rezistență

Termen scurt

Weak Bullish Evidence

Termen mediu

Bearish Evidence

Termen lung

Neutral Evidence

Sentiment

By Acuity

38 / 352 Clasament în Sănătate

Sentimentul știrilor

Evidențe foarte puternice de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
help-icon Live chat